Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 14, 2019 - Issue
Submit an article Journal homepage
140
Views
12
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis

Igor Z Barjaktarevic1 Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USAORCID Iconhttps://orcid.org/0000-0002-8096-0858
ORCID Icon,
Russell G Buhr1 Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA;2 Department of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USAORCID Iconhttps://orcid.org/0000-0001-6159-7435
ORCID Icon,
Xiaoyan Wang3 Department of General Internal Medicine and Health Services Research, University of California, Los Angeles, Los Angeles, CA, USA
,
Scott Hu1 Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
,
David Couper4 Department of Medicine, University of North Carolina, Chapel Hill, NC, USAORCID Iconhttps://orcid.org/0000-0002-4313-9235
ORCID Icon,
Wayne Anderson4 Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
,
Richard E Kanner5 Department of Medicine, University of Utah, Salt Lake City, UT, USAORCID Iconhttps://orcid.org/0000-0001-6915-599X
ORCID Icon,
Robert Paine III5 Department of Medicine, University of Utah, Salt Lake City, UT, USA
,
Surya P Bhatt6 Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USAORCID Iconhttps://orcid.org/0000-0002-8418-4497
ORCID Icon,
Nirav R Bhakta7 Department of Medicine, University of California, San Francisco, San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-2135-7012
ORCID Icon,
Mehrdad Arjomandi7 Department of Medicine, University of California, San Francisco, San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-0116-9217
ORCID Icon,
Robert J Kaner8 Department of Medicine, Weill Cornell Weill Cornell Medical Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0003-0527-576X
ORCID Icon,
Cheryl S Pirozzi5 Department of Medicine, University of Utah, Salt Lake City, UT, USAORCID Iconhttps://orcid.org/0000-0002-1533-1916
ORCID Icon,
Jeffrey L Curtis9 Department of Medicine, University of Michigan, Ann Arbor, MI, USA;10 Medicine Service, VA Ann Arbor Healthcare System, Ann Arbor, MI, USAORCID Iconhttps://orcid.org/0000-0001-5191-4847
ORCID Icon,
Wanda K O’Neal4 Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
,
Prescott G Woodruff7 Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
,
MeiLan K Han9 Department of Medicine, University of Michigan, Ann Arbor, MI, USA
,
Fernando J Martinez8 Department of Medicine, Weill Cornell Weill Cornell Medical Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-2412-3182
ORCID Icon,
Nadia Hansel11 Department of Medicine, John Hopkins University, Baltimore, MD, USA
,
James Michael Wells6 Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
,
Victor E Ortega12 Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
,
Eric A Hoffman13 Department of Medicine, University of Iowa, Iowa City, IA, USAORCID Iconhttps://orcid.org/0000-0001-8456-9437
ORCID Icon,
Claire M Doerschuk4 Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
,
Victor Kim14 Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USAORCID Iconhttps://orcid.org/0000-0002-1385-1571
ORCID Icon,
Mark T Dransfield6 Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
,
M Bradley Drummond4 Department of Medicine, University of North Carolina, Chapel Hill, NC, USAORCID Iconhttps://orcid.org/0000-0002-6968-4610
ORCID Icon,
Russell Bowler15 Department of Medicine, National Jewish Health Systems, Denver, CO, USA
,
Gerard Criner14 Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA
,
Stephanie A Christenson7 Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
,
Bonnie Ronish5 Department of Medicine, University of Utah, Salt Lake City, UT, USA
,
Stephen P Peters12 Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USAORCID Iconhttps://orcid.org/0000-0003-4176-7999
ORCID Icon,
Jerry A Krishnan16 Department of Medicine, University of Illinois at Chicago, Chicago, IL, USAORCID Iconhttps://orcid.org/0000-0001-5525-4778
ORCID Icon,
Donald P Tashkin1 Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
,
Christopher B Cooper1 Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USACorrespondence[email protected]
& On behalf of the NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) show all
Pages 2927-2938 | Published online: 20 Dec 2019

References

  • Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946.15219010
  • Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–968.16264058
  • Miller MR, Hankinson JA, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.0003480516055882
  • Hanania NA, Sharafkhaneh A, Celli B, et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011;12:6. doi:10.1186/1465-9921-12-621219660
  • Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;31(4):742–750. doi:10.1183/09031936.0012960718256071
  • Walker PP, Calverley PM. The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease. COPD. 2008;5(3):147–152. doi:10.1080/1541255080209292818568838
  • O’Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis. 1993;148(5):1351–1357. doi:10.1164/ajrccm/148.5.13518239175
  • Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58(8):659–664. doi:10.1136/thorax.58.8.65912885978
  • Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012;67(8):701–708. doi:10.1136/thoraxjnl-2011-20145822696176
  • Quanjer PH, Ruppel GL, Langhammer A, et al. Bronchodilator response in FVC is larger and more relevant than in FEV1 in severe airflow obstruction. Chest. 2017;151(5):1088–1098.28040521
  • Ben Saad H, Préfaut C, Tabka Z, Zbidi A, Hayot M. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Pulm Pharmacol Ther. 2008;21(5):767–773.18555715
  • Singh D, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.30846476
  • Gunen H, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005;26(2):234–241.16055870
  • Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest. 2007;131(3):696–704.17356082
  • Couper D, LaVange LM, Han M. Design of the subpopulations and intermediate outcomes in COPD study (SPIROMICS). Thorax. 2014;69(5):491–494.
  • Vestbo J, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365.22878278
  • Sieren JP, Newell JD Jr, Barr RG, et al. SPIROMICS protocol for multicenter quantitative computed tomography to phenotype the lungs. Am J Respir Crit Care Med. 2016;194(7):794–806.27482984
  • Boes JL, Hoff BA, Bule M, et al. Parametric response mapping monitors temporal changes on lung CT scans in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS). Acad Radiol. 2015;22(2):186–194.25442794
  • Anderson WH, Ha JW, Couper DJ, et al. Variability in objective and subjective measures affects baseline values in studies of patients with COPD. PLoS One. 2017;12(9):e0184606.28934249
  • Celli BR, Tashkin DP, Rennard SI, et al. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respir Med. 2011;105(8):1176–1188.21531124
  • Barjaktarevic I, Kaner R, Buhr RG, et al. Bronchodilator responsiveness or reversibility in asthma and COPD - a need for clarity. Int J Chron Obstruct Pulmon Dis. 2018;13:3511–3513.30498341
  • Muller V, Gálffy G, Orosz M, et al. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol easyhaler data. Int J Chron Obstruct Pulmon Dis. 2016;11:93–101.26834466
  • Toren K, Bake B, Olin AC, et al. Measures of bronchodilator response of FEV1, FVC and SVC in a Swedish general population sample aged 50–64 years, the SCAPIS pilot study. Int J Chron Obstruct Pulmon Dis. 2017;12:973–980.28356729
  • Fingleton J, Weatherall M, Beasley R. Bronchodilator responsiveness: interpret with caution. Thorax. 2012;67(8):667–668.22693176
  • Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(12):956–967.29146301
  • Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124(5):1743–1748.14605043
  • Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2689–2697.15215485
  • Tan WC, Vollmer WM, Lamprecht B, et al. Worldwide patterns of bronchodilator responsiveness: results from the burden of obstructive lung disease study. Thorax. 2012;67(8):718–726. doi:10.1136/thoraxjnl-2011-20144522544896
  • Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192. doi:10.1056/NEJMoa110548221991892
  • Ortega F, Marquez-Martin E, Valencia B, et al. Impact of bronchodilator responsiveness on quality of life and exercise capacity in patients with COPD. Respir Care. 2014;59(1):81–89. doi:10.4187/respcare.0239923737547
  • Tashkin DP. Is it asthma, COPD, or something in between, and does it matter?. Respir Care. 2012;57(8):1354–1356. doi:10.4187/respcare.0197022867646
  • Dorinsky PM, Reisner C, Ferguson GT, et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest. 1999;115(4):966–971. doi:10.1378/chest.115.4.96610208193

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.